Ontology highlight
ABSTRACT:
SUBMITTER: Chan JA
PROVIDER: S-EPMC4469068 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature
Chan Jennifer A JA Ryan David P DP Zhu Andrew X AX Abrams Thomas A TA Wolpin Brian M BM Malinowski Paige P Regan Eileen M EM Fuchs Charles S CS Kulke Matthew H MH
Endocrine-related cancer 20120914 5
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate the safety and feasibility of combining pasireotide with everolimus in patients with advanced neuroendocrine tumors. Cohorts of patients with advanced neuroendocrine tumors were treated with escalating doses of pasireotide (600-1200 μg s.c. b.i.d., f ...[more]